Literature DB >> 10548525

Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes.

J Rieusset1, J Auwerx, H Vidal.   

Abstract

To better define the mechanism of action of the thiazolidinediones, we incubated freshly isolated human adipocytes with rosiglitazone and investigated the changes in mRNA expression of genes encoding key proteins of adipose tissue functions. Rosiglitazone (10(-6) M, 4 h) increased p85alphaphosphatidylinositol 3-kinase (p85alphaPI-3K) and uncoupling protein-2 mRNA levels and decreased leptin expression. The mRNA levels of insulin receptor, IRS-1, Glut 4, lipoprotein lipase, hormone-sensitive lipase, acylation-stimulating protein, fatty acid transport protein-1, angiotensinogen, plasminogen activator inhibitor-1, and PPARgamma1 and gamma2 were not modified by rosiglitazone treatment. Activation of RXR, the partner of PPARgamma, in the presence of rosiglitazone, increased further p85alphaPI-3K and UCP2 mRNA levels and produced a significant augmentation of Glut 4 expression. Because p85alphaPI-3K is a major component of insulin action, the induction of its expression might explain, at least in part, the insulin-sensitizing effect of the thiazolidinediones. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548525     DOI: 10.1006/bbrc.1999.1657

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.

Authors:  G D Tan; B A Fielding; J M Currie; S M Humphreys; M Désage; K N Frayn; M Laville; H Vidal; F Karpe
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

Review 2.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 3.  The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus.

Authors:  Venu Gopal Jonnalagadda; Allam Venkata Sita Ram Raju; Srinivas Pittala; Afsar Shaik; Nilakash Annaji Selkar
Journal:  Adv Pharm Bull       Date:  2014-02-07

Review 4.  UCP2, a mitochondrial protein regulated at multiple levels.

Authors:  Massimo Donadelli; Ilaria Dando; Claudia Fiorini; Marta Palmieri
Journal:  Cell Mol Life Sci       Date:  2013-06-27       Impact factor: 9.261

5.  Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes.

Authors:  R Hernandez; T Teruel; M Lorenzo
Journal:  Diabetologia       Date:  2003-11-01       Impact factor: 10.122

6.  Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.

Authors:  Guoqiang Jiang; Qing Dallas-Yang; Subarna Biswas; Zhihua Li; Bei B Zhang
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

7.  PPARs in the Renal Regulation of Systemic Blood Pressure.

Authors:  Tamás Roszer; Mercedes Ricote
Journal:  PPAR Res       Date:  2010-06-08       Impact factor: 4.964

8.  Cross-Talk between PPARgamma and Insulin Signaling and Modulation of Insulin Sensitivity.

Authors:  Anna Leonardini; Luigi Laviola; Sebastio Perrini; Annalisa Natalicchio; Francesco Giorgino
Journal:  PPAR Res       Date:  2010-02-23       Impact factor: 4.964

Review 9.  The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.

Authors:  Norman L Eberhardt; Stefan K G Grebe; Bryan McIver; Honey V Reddi
Journal:  Mol Cell Endocrinol       Date:  2009-10-31       Impact factor: 4.102

Review 10.  Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  Antona J Wagstaff; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.